Associations of serum sclerostin levels with body composition, pulmonary function, and exacerbations in COPD patients.

Autor:	Amado CA; Department of Pulmonology, Hospital Universitario Marqués de Valdecilla. Santander, Spain; University of Cantabria. Santander, Spain; IDIVAL (Instituto de Investigación Biomédica de Cantabria). Santander, Spain. Electronic address: carlosantonio.amado@scsalud.es., García-Unzueta M; University of Cantabria. Santander, Spain; Department of Biochemistry, Hospital Universitario Marqués de Valdecilla. Santander, Spain., Agüero J; Department of Pulmonology, Hospital Universitario Marqués de Valdecilla. Santander, Spain., Martín-Audera P; Department of Biochemistry, Hospital Universitario Marqués de Valdecilla. Santander, Spain., Fueyo P; University of Cantabria. Santander, Spain., Lavín BA; Department of Biochemistry, Hospital Universitario Marqués de Valdecilla. Santander, Spain., Guerra AR; Department of Biochemistry, Hospital Universitario Marqués de Valdecilla. Santander, Spain., Muñoz P; Servicio Cántabro de Salud. Santander, Spain., Tello S; Department of Pulmonology, Hospital Universitario Marqués de Valdecilla. Santander, Spain., Berja A; Department of Biochemistry, Hospital Universitario Marqués de Valdecilla. Santander, Spain., Casanova C; Servicio de Neumología-Unidad de Investigación, Hospital Universitario La Candelaria, Universidad de La Laguna, Tenerife, Spain.
Jazyk:	angličtina
Zdroj:	Pulmonology [Pulmonology] 2024 Nov-Dec; Vol. 30 (6), pp. 512-521. Date of Electronic Publication: 2022 Aug 11.
DOI:	10.1016/j.pulmoe.2022.06.003
Abstrakt:	Background: In COPD, the bronchial epithelium shows a pathologically activated Wnt pathway. Sclerostin (SOST) is a secreted glycoprotein that is associated with bone metabolism and blocks the Wnt pathway. We hypothesized that low sclerostin levels might be associated with lung function and COPD exacerbations in patients. Methods: We studied 139 outpatients with stable COPD and normal kidney function. We assessed the serum levels of SOST and bone metabolism parameters, body composition, clinical characteristics and lung function at baseline. We followed the patients prospectively for 12 months after enrolment. Moderate exacerbations and hospital admissions were recorded during follow-up. Results: The serum SOST levels were 23.98±7.6 pmol/l (men: 25.5±7.7 pmol/l, women: 20.3±5.9 pmol/l (p < 0.001)). SOST showed correlations with age (r = 0.36), FFMI (r = 0.38), FEV1 (r = 0.27), DLCO (r = 0.39), 6MWD (r = 0.19) and CAT (r = -0.24). In multivariate linear regression analysis, only age (beta=0.264) and FFMI (beta=1.241) remained significant. SOST showed a significant negative correlation with serum phosphorus (r = -0.29). Cox proportional risk analysis indicated that patients in the lower tertile of SOST levels were at higher risk of moderate COPD exacerbation (HR 2.015, CI95% 1.136-3.577, p = 0.017) and hospital admission due to COPD (HR 5.142, CI95% 1.380-19.158, p = 0.015) than the rest of the patients. Conclusions: SOST levels are associated with body composition and lung function in patients with COPD. Furthermore, lower SOST levels predict a higher risk of exacerbations and hospitalization. Competing Interests: Declaration of interests None. (Copyright © 2022 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu